Skip to content

Intrathecal morphine for endoscopic spine surgery: A prospective dose-finding study

Intrathecal morphine for endoscopic spine surgery: A prospective dose-finding study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200067060
Enrollment
Unknown
Registered
2022-12-26
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation

Interventions

Test group:Intrathecal morphine

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age 18 or older; (2) Undergoing single-segment percutaneous endoscopic lumbar discectomy surgery; (3) The ASA score is less than < 3.

Exclusion criteria

Exclusion criteria: (1) Use of a strong opioid (morphine, oxycodone, fentanyl, pethidine, or methadone) within 72 hours (2) Contraindications to the use of lumbar anesthesia or morphine, those who have had adverse events with previous morphine use, and those who are addicted to opioids (3) There are contraindications to the use of NSAIDs analgesics (4) Itchy skin disease, prostatic hyperplasia/history of previous urinary retention; (5) Respiratory diseases, including OSAS, chronic obstructive pulmonary disease, asthma and chronic cough; (6) Those who are unable to cooperate with mental disorders/cognitive impairments, etc.; (7) Pregnant and lactating women; (8) Vulnerable groups.

Design outcomes

Primary

MeasureTime frame
Overall pain scale of the surgery;

Secondary

MeasureTime frame
Additional analgesia during and after operation.;Oswestry Disability Index;Surgical area pain intensity;

Countries

China

Contacts

Public ContactSun Haolin

Peking University First Hospital

sunhaolin@vip.163.com13681146156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026